BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.50), $1.29 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $168 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.